

# **Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity**

<https://marketpublishers.com/r/AE3E9F1F4FBEEEN.html>

Date: October 2020

Pages: 115

Price: US\$ 2,550.00 (Single User License)

ID: AE3E9F1F4FBEEEN

## **Abstracts**

Asia Pacific pharmaceutical contract manufacturing market will grow by 7.6% annually with a total addressable market cap of \$489.1 billion over 2020-2030 owing to the rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity.

Highlighted with 38 tables and 53 figures, this 116-page report “Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country.

Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Pharmaceutical Industry

Biopharmaceutical Industry

Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Active Pharmaceutical Ingredients (API)

Branded API Manufacturing

Generic API Manufacturing

Finished Dosage Formulations (FDF)

Solid Dosage

Oral Liquids

Parenteral/Injectables

Other FDFs

Secondary Packaging

Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Clinical Manufacturing

Commercial Manufacturing

Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Sterile Products

Non-Sterile Products

Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Infectious Diseases

Oncology

Metabolic Disorders

Cardiovascular Disorders

Central Nervous System

Pulmonary Disorders

Gastrointestinal Disorders

Other Therapeutic Applications

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Aenova Group

Baxter BioPharma Solutions

Boehringer Ingelheim  
Catalent Inc.  
Famar S.A.  
Hospira, Inc.  
Jubilant Life Sciences Ltd.  
Lonza Group  
Patheon Inc.  
Pfizer CentreSource  
Recipharm AB  
Vetter Pharma International GmbH

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

## Contents

### **1 INTRODUCTION**

- 1.1 Industry Definition and Research Scope
  - 1.1.1 Industry Definition
  - 1.1.2 Research Scope
- 1.2 Research Methodology
  - 1.2.1 Overview of Market Research Methodology
  - 1.2.2 Market Assumption
  - 1.2.3 Secondary Data
  - 1.2.4 Primary Data
  - 1.2.5 Data Filtration and Model Design
  - 1.2.6 Market Size/Share Estimation
  - 1.2.7 Research Limitations
- 1.3 Executive Summary

### **2 MARKET OVERVIEW AND DYNAMICS**

- 2.1 Market Size and Forecast
  - 2.1.1 Impact of COVID-19 on World Economy
  - 2.1.2 Impact of COVID-19 on the Market
- 2.2 Major Growth Drivers
- 2.3 Market Restraints and Challenges
- 2.4 Emerging Opportunities and Market Trends
- 2.5 Porter's Fiver Forces Analysis

### **3 SEGMENTATION OF ASIA PACIFIC MARKET BY CATEGORY**

- 3.1 Market Overview by Category
- 3.2 Pharmaceutical Industry
- 3.3 Biopharmaceutical Industry

### **4 SEGMENTATION OF ASIA PACIFIC MARKET BY PRODUCT**

- 4.1 Market Overview by Product
- 4.2 Active Pharmaceutical Ingredients (API)
  - 4.2.1 Branded API Manufacturing
  - 4.2.2 Generic API Manufacturing

#### 4.3 Finished Dosage Formulations (FDF)

4.3.1 Solid Dosage

4.3.2 Oral Liquids

4.3.3 Parenteral/Injectables

4.3.4 Other FDFs

#### 4.4 Secondary Packaging

### **5 SEGMENTATION OF ASIA PACIFIC MARKET BY PHASE**

5.1 Market Overview by Phase

5.2 Clinical Manufacturing

5.3 Commercial Manufacturing

### **6 SEGMENTATION OF ASIA PACIFIC MARKET BY TYPE**

6.1 Market Overview by Type

6.2 Sterile Products

6.3 Non-Sterile Products

### **7 SEGMENTATION OF ASIA PACIFIC MARKET BY THERAPEUTIC APPLICATION**

7.1 Market Overview by Therapeutic Application

7.2 Infectious Diseases

7.3 Oncology

7.4 Metabolic Disorders

7.5 Cardiovascular Disorders

7.6 Central Nervous System

7.7 Pulmonary Disorders

7.8 Gastrointestinal Disorders

7.9 Other Therapeutic Applications

### **8 ASIA-PACIFIC MARKET 2019-2030 BY COUNTRY**

8.1 Overview of Asia-Pacific Market

8.2 Japan

8.3 China

8.4 Australia

8.5 India

8.6 South Korea

## 8.7 Rest of APAC Region

# 9 COMPETITIVE LANDSCAPE

## 9.1 Overview of Key Vendors

## 9.2 New Product Launch, Partnership, Investment, and M&A

## 9.3 Company Profiles

Aenova Group

Baxter BioPharma Solutions

Boehringer Ingelheim

Catalent Inc.

Famar S.A.

Hospira, Inc.

Jubilant Life Sciences Ltd.

Lonza Group

Patheon Inc.

Pfizer CentreSource

Recipharm AB

Vetter Pharma International GmbH

# 10 INVESTING IN ASIA PACIFIC MARKET: RISK ASSESSMENT AND MANAGEMENT

## 10.1 Risk Evaluation of Asia Pacific Market

## 10.2 Critical Success Factors (CSFs)

## Related Reports and Products



## List Of Tables

### LIST OF TABLES

Table 1. Snapshot of Asia Pacific Pharmaceutical Contract Manufacturing Market, 2019-2030

Table 2. Growth Rate of World Real GDP, 2017-2021

Table 3. Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical Contract Manufacturing Market

Table 4. Asia Pacific Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, \$ bn

Table 5. Asia Pacific Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, \$ bn

Table 6. Asia Pacific Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, \$ bn

Table 7. Asia Pacific Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, \$ bn

Table 8. Asia Pacific Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, \$ bn

Table 9. Asia Pacific Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, \$ bn

Table 10. Asia Pacific Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, \$ bn

Table 11. APAC Pharmaceutical Contract Manufacturing Market by Country, 2019-2030, \$ bn

Table 12. Japan Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, \$ bn

Table 13. Japan Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, \$ bn

Table 14. Japan Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, \$ bn

Table 15. China Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, \$ bn

Table 16. China Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, \$ bn

Table 17. China Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, \$ bn

Table 18. Australia Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, \$ bn

Table 19. Australia Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, \$ bn

Table 20. Australia Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, \$ bn

Table 21. India Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, \$ bn

Table 22. India Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, \$ bn

Table 23. India Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, \$ bn

Table 24. South Korea Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, \$ bn

Table 25. South Korea Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, \$ bn

Table 26. South Korea Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, \$ bn

Table 27. Pharmaceutical Contract Manufacturing Market in Rest of APAC by Country, 2019-2030, \$ bn

Table 28. Aenova Group: Company Snapshot

Table 29. Aenova Group: Business Segmentation

Table 30. Aenova Group: Product Portfolio

Table 31. Aenova Group: Revenue, 2016-2018, \$ bn

Table 32. Aenova Group: Recent Developments

Table 33. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030

Table 34. Critical Success Factors and Key Takeaways

## List Of Figures

### LIST OF FIGURES

Figure 1. Research Method Flow Chart

Figure 2. Breakdown of Primary Research

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation

Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030

Figure 5. Asia Pacific Pharmaceutical Contract Manufacturing Market, 2019-2030, \$ bn

Figure 6. Impact of COVID-19 on Business

Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market

Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market

Figure 9. Investment Opportunity Analysis

Figure 10. Porter's Fiver Forces Analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market

Figure 11. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue

Figure 12. Asia Pacific Addressable Market Cap in 2020-2030 by Category, Value (\$ bn) and Share (%)

Figure 13. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, \$ bn

Figure 14. Asia Pacific Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, \$ bn

Figure 15. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue

Figure 16. Asia Pacific Addressable Market Cap in 2020-2030 by Product, Value (\$ bn) and Share (%)

Figure 17. Asia Pacific Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, \$ bn

Figure 18. Asia Pacific Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, \$ bn

Figure 19. Asia Pacific Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, \$ bn

Figure 20. Asia Pacific Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, \$ bn

Figure 21. Asia Pacific Pharmaceutical Contract Manufacturing Market: Solid Dosage,

2019-2030, \$ bn

Figure 22. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, \$ bn

Figure 23. Asia Pacific Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, \$ bn

Figure 24. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, \$ bn

Figure 25. Asia Pacific Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, \$ bn

Figure 26. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue

Figure 27. Asia Pacific Addressable Market Cap in 2020-2030 by Phase, Value (\$ bn) and Share (%)

Figure 28. Asia Pacific Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, \$ bn

Figure 29. Asia Pacific Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, \$ bn

Figure 30. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue

Figure 31. Asia Pacific Addressable Market Cap in 2020-2030 by Type, Value (\$ bn) and Share (%)

Figure 32. Asia Pacific Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, \$ bn

Figure 33. Asia Pacific Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, \$ bn

Figure 34. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue

Figure 35. Asia Pacific Addressable Market Cap in 2020-2030 by Therapeutic Application, Value (\$ bn) and Share (%)

Figure 36. Asia Pacific Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, \$ bn

Figure 37. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, \$ bn

Figure 38. Asia Pacific Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, \$ bn

Figure 39. Asia Pacific Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, \$ bn

Figure 40. Asia Pacific Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, \$ bn

Figure 41. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, \$ bn

Figure 42. Asia Pacific Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, \$ bn

Figure 43. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, \$ bn

Figure 44. Breakdown of APAC Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue

Figure 45. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value (\$ bn) and Share (%)

Figure 46. Pharmaceutical Contract Manufacturing Market in Japan, 2019-2030, \$ bn

Figure 47. Pharmaceutical Contract Manufacturing Market in China, 2019-2030, \$ bn

Figure 48. Pharmaceutical Contract Manufacturing Market in Australia, 2019-2030, \$ bn

Figure 49. Pharmaceutical Contract Manufacturing Market in India, 2019-2030, \$ bn

Figure 50. Pharmaceutical Contract Manufacturing Market in South Korea, 2019-2030, \$ bn

Figure 51. Pharmaceutical Contract Manufacturing Market in Rest of APAC, 2019-2030, \$ bn

Figure 52. Growth Stage of Asia Pacific Pharmaceutical Contract Manufacturing Industry over the Forecast Period

## I would like to order

Product name: Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity

Product link: <https://marketpublishers.com/r/AE3E9F1F4FBEEN.html>

Price: US\$ 2,550.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AE3E9F1F4FBEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970